安科生物
(300009)
| 流通市值：104.33亿 | | | 总市值：141.68亿 |
| 流通股本：12.30亿 | | | 总股本：16.71亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 541,715,939.09 | 2,646,519,767.58 | 1,962,590,112.69 | 1,292,187,881.95 |
| 营业收入 | 541,715,939.09 | 2,646,519,767.58 | 1,962,590,112.69 | 1,292,187,881.95 |
| 二、营业总成本 | 352,814,069.35 | 1,835,649,613.89 | 1,345,964,715.95 | 885,306,876.29 |
| 营业成本 | 132,230,483.02 | 643,158,185.54 | 471,560,303.44 | 304,328,562.42 |
| 税金及附加 | 5,106,701.74 | 22,579,554.18 | 15,976,758.03 | 10,818,890.74 |
| 销售费用 | 145,987,437.14 | 797,023,675.17 | 597,938,935.41 | 395,373,392.28 |
| 管理费用 | 33,815,825.82 | 150,904,536.74 | 112,101,894.95 | 76,117,501.31 |
| 研发费用 | 36,039,441.22 | 219,446,120.51 | 145,384,774.02 | 95,820,124.67 |
| 财务费用 | -365,819.59 | 2,537,541.75 | 3,002,050.1 | 2,848,404.87 |
| 其中:利息费用 | 110,160.36 | 1,934,682.41 | 1,674,560.52 | 1,162,065.62 |
| 其中:利息收入 | 467,024.45 | 3,480,666.32 | 2,612,900.96 | 1,805,832.05 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 4,161,698.81 | 1,881,347.93 | 1,771,625.65 | -986,558.98 |
| 加:投资收益 | 831,706.02 | 18,203,718.45 | 11,267,643.47 | 11,188,455.65 |
| 资产处置收益 | 0 | 6,301,460.04 | 676,184.15 | 520,388.61 |
| 资产减值损失(新) | 0 | -17,471,471.06 | -3,820,281.73 | -3,099,669.73 |
| 信用减值损失(新) | -218,358.35 | -10,574,169.32 | -976,532.7 | -1,002,141.61 |
| 其他收益 | 3,572,373.8 | 27,750,020.12 | 23,956,711.18 | 18,829,280.91 |
| 四、营业利润 | 197,249,290.02 | 836,961,059.85 | 649,500,746.76 | 432,330,760.51 |
| 加:营业外收入 | 31,690.99 | 57,733.4 | 4,018.25 | 5,353.8 |
| 减:营业外支出 | 150,059.38 | 3,860,692.06 | 820,515.07 | 255,092.39 |
| 五、利润总额 | 197,130,921.63 | 833,158,101.19 | 648,684,249.94 | 432,081,021.92 |
| 减:所得税费用 | 24,966,174.55 | 85,819,395.5 | 86,062,811.87 | 57,527,406.54 |
| 六、净利润 | 172,164,747.08 | 747,338,705.69 | 562,621,438.07 | 374,553,615.38 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 172,164,747.08 | 747,338,705.69 | 562,621,438.07 | 374,553,615.38 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 167,587,671.9 | 735,192,705.68 | 551,483,266.04 | 366,517,170.34 |
| 少数股东损益 | 4,577,075.18 | 12,146,000.01 | 11,138,172.03 | 8,036,445.04 |
| 扣除非经常损益后的净利润 | 159,363,883.19 | 668,054,957.26 | 518,981,844.93 | 341,883,418.97 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.44 | 0.33 | 0.22 |
| (二)稀释每股收益 | 0.1 | 0.44 | 0.33 | 0.22 |
| 八、其他综合收益 | 22,265,954.79 | 64,761,046.22 | -78,746,995.87 | -71,008,287.24 |
| 归属于母公司股东的其他综合收益 | 22,265,954.79 | 64,761,046.22 | -78,746,995.87 | -71,008,287.24 |
| 九、综合收益总额 | 194,430,701.87 | 812,099,751.91 | 483,874,442.2 | 303,545,328.14 |
| 归属于母公司股东的综合收益总额 | 189,853,626.69 | 799,953,751.9 | 472,736,270.17 | 295,508,883.1 |
| 归属于少数股东的综合收益总额 | 4,577,075.18 | 12,146,000.01 | 11,138,172.03 | 8,036,445.04 |
| 公告日期 | 2026-04-24 | 2026-03-31 | 2025-10-28 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |